Www.umu.se



Methods used in the Northern Sweden Health and Disease study (NSHDS)This document is a summary of methods and algorithms constructed for optimal use of the phenotypic data stored for participants in the NSHDS biobank. There are a few shifts in methodology used during the period samples and data have been collected, which are relevant primarily in the time-trend analyses. These shifts are related to blood pressure and blood lipids, and are described in detail later on in this document. Further information of the NSHDS cohorts can be found at the webpage: 2, edited 2020-01-20 and 2020-10-02Editor:Anders JohanssonScientific board: Stefan S?derberg, Johan Hultdin & Patrik WennbergReferees:Kjell Grankvist, Medicinsk Biovetenskap, Ume? UniversitetMarie Eriksson, Statistik/Handelsh?gskolan, Ume? Universitet.Robert Johansson and Ingvar Bergdahl, both at the Biobank Research Unit, took part in the discussions and recalculation of statistics during the revision year 2020. Content:Methods used in the VIP studypage 2-3Methods used in the MONICA studypage 4-5Methods used in the “Mammographic screening project”page 6Recommendations for interpretation of outlier valuespage 6Conversion of blood pressure, recumbent to sitting-VIP page 7Algorithms for conversion of blood lipids-VIPpage 8Transformation of data blood lipids-MONICApage 9-11V?sterbotten Intervention Program (VIP), Methods for CVD risk factorsCohort1985-1991: examinations could be performed either in the morning or after lunch and hence the fasting period was at least 8 hours or at least 4 hours, respectively.From 1992: A fasting period of minimum of 8 hours before blood sampling required. In practice, this implies an overnight fast and blood sampling is done in the morning.Blood pressure1985-2000 measured manually once usually to the nearest 5 or 10 mm with a mercury sphygmomanometer after 5 min rest with the subject in a recumbent position. During 2000-2008 the health care centers increasingly and after their own decisions shifted to automated digital blood pressure measurements using calibrated devices. From 2009 09 01: Measured twice with mercury sphygmomanometer (precision 2 mm) or automated digital blood pressure measurements using calibrated devices after 5 min rest with the subject in a sitting position. The mean of the two measurements of systolic and diastolic blood pressures are recorded.Transformation algorithms are available at EBF to be used on study populations including data both before and after this date (see page 2).Blood-glucose1985-Oral glucose Tolerance test performed according to WHO standards (2).Fasting and 2-hour glucose analyzed on capillary plasma on a Reflotron Bench top analyzer (Roche Diagnostics).From. 2004: Fasting and 2-hour glucose analyzed on a Hemocuebench-top HemoCue? Glucose?analyzer (HemoCue AB, ?ngelholm, Sweden) (1).Reflotron and Hemocue analyzers regularly tested in a calibration scheme provided byEQUALIS, the External Quality Assurance in Laboratory Medicine in Sweden.Plasma lipids1985-P-Cholesterol and P-Triglycerides were analyzed on a Reflotron Bench top analyzer (Roche Diagnostics).From 2009-09-01: Lipids (P-cholesterol, P-triglycerides, P-LDL-cholesterol and P-HDL-cholesterol) analyses with routine methods at clinical chemistry department of the local hospital.We have examined the material where there are measurement values (P-chol, P-triglyc.) from both methods and the difference in mean and median values is only 2-3%. Therefore, we recommend that you do not use any algorithm, but the methods are comparable. However, it should be kept in mind that for triglycerides, the min value with the old method is = 0.8.Height1985-Without shoes. Measured to the nearest cm using a calibrated wall mounted height rod or height rod that is mount onto the scale.Weight1985-Light indoor clothing. Measured to the nearest kg using a calibrated scale.WaistFrom 2003-Measured with an inelastic tape, on the skin, to the nearest cm, in the midway between the lowest palpable rib and top of the iliac crest. The subject in a standing position and after a calm exhalation. References, V?sterbotten Intervention Program (VIP)1. Norberg M, Wall S, Boman K, Weinehall L. The Vasterbotten Intervention Programme: background, design and implications. Glob Health Action. 2010;3.2. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999.MONICA, Methods for CVD risk factorsCohort PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Fcmlrc3NvbjwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+

PFJlY051bT4xNjU8L1JlY051bT48RGlzcGxheVRleHQ+KDEsIDIpPC9EaXNwbGF5VGV4dD48cmVj

b3JkPjxyZWMtbnVtYmVyPjE2NTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF

TiIgZGItaWQ9ImFlNXpld3R2M3ZzZXhrZTlld2N2dHM5azJmYXJ4MnJheHI1dCIgdGltZXN0YW1w

PSIxMzE3MTYxMzg3Ij4xNjU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PkVyaWtzc29uLCBNLjwvYXV0aG9yPjxhdXRob3I+SG9sbWdyZW4sIEwuPC9hdXRob3I+PGF1dGhv

cj5KYW5sZXJ0LCBVLjwvYXV0aG9yPjxhdXRob3I+SmFuc3NvbiwgSi4gSC48L2F1dGhvcj48YXV0

aG9yPkx1bmRibGFkLCBELjwvYXV0aG9yPjxhdXRob3I+U3RlZ21heXIsIEIuPC9hdXRob3I+PGF1

dGhvcj5Tb2RlcmJlcmcsIFMuPC9hdXRob3I+PGF1dGhvcj5FbGlhc3NvbiwgTS48L2F1dGhvcj48

L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFB1Ymxp

YyBIZWFsdGggYW5kIENsaW5pY2FsIE1lZGljaW5lLCBVbWVhIFVuaXZlcnNpdHksIFVtZWEsIFN3

ZWRlbi4gbWFyaWUuZXJpa3Nzb25AbWVkaWNpbi51bXUuc2U8L2F1dGgtYWRkcmVzcz48dGl0bGVz

Pjx0aXRsZT5MYXJnZSBpbXByb3ZlbWVudHMgaW4gbWFqb3IgY2FyZGlvdmFzY3VsYXIgcmlzayBm

YWN0b3JzIGluIHRoZSBwb3B1bGF0aW9uIG9mIG5vcnRoZXJuIFN3ZWRlbjogdGhlIE1PTklDQSBz

dHVkeSAxOTg2LTIwMDk8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SiBJbnRlcm4gTWVkPC9zZWNv

bmRhcnktdGl0bGU+PGFsdC10aXRsZT5KIEludGVybiBNZWQ8L2FsdC10aXRsZT48L3RpdGxlcz48

cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIEludGVybiBNZWQ8L2Z1bGwtdGl0bGU+PGFiYnItMT5K

b3VybmFsIG9mIGludGVybmFsIG1lZGljaW5lPC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVy

aW9kaWNhbD48ZnVsbC10aXRsZT5KIEludGVybiBNZWQ8L2Z1bGwtdGl0bGU+PGFiYnItMT5Kb3Vy

bmFsIG9mIGludGVybmFsIG1lZGljaW5lPC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+

MjE5LTMxPC9wYWdlcz48dm9sdW1lPjI2OTwvdm9sdW1lPjxudW1iZXI+MjwvbnVtYmVyPjxlZGl0

aW9uPjIwMTAvMTIvMTc8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3Jk

PjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+QW50aWNob2xlc3RlcmVtaWMgQWdlbnRz

L3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5CbG9vZCBQcmVzc3VyZS9waHlzaW9s

b2d5PC9rZXl3b3JkPjxrZXl3b3JkPkJvZHkgTWFzcyBJbmRleDwva2V5d29yZD48a2V5d29yZD5D

YXJkaW92YXNjdWxhciBEaXNlYXNlcy8qZXBpZGVtaW9sb2d5LypldGlvbG9neS9waHlzaW9wYXRo

b2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+Q2hvbGVzdGVyb2wvYmxvb2Q8L2tleXdvcmQ+PGtleXdv

cmQ+RGlhYmV0ZXMgTWVsbGl0dXMvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkVkdWNh

dGlvbmFsIFN0YXR1czwva2V5d29yZD48a2V5d29yZD5FcGlkZW1pb2xvZ2ljIE1ldGhvZHM8L2tl

eXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48

a2V5d29yZD5IeXBlcnRlbnNpb24vY29tcGxpY2F0aW9ucy9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+

PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5

d29yZD5PYmVzaXR5L2NvbXBsaWNhdGlvbnMvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3Jk

PlNtb2tpbmcvYWR2ZXJzZSBlZmZlY3RzL2VwaWRlbWlvbG9neS90cmVuZHM8L2tleXdvcmQ+PGtl

eXdvcmQ+U3dlZGVuL2VwaWRlbWlvbG9neTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVh

cj4yMDExPC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+RmViPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0

ZXM+PGlzYm4+MTM2NS0yNzk2IChFbGVjdHJvbmljKSYjeEQ7MDk1NC02ODIwIChMaW5raW5nKTwv

aXNibj48YWNjZXNzaW9uLW51bT4yMTE1ODk4MjwvYWNjZXNzaW9uLW51bT48d29yay10eXBlPlJl

c2VhcmNoIFN1cHBvcnQsIE5vbi1VLlMuIEdvdiZhcG9zO3Q8L3dvcmstdHlwZT48dXJscz48cmVs

YXRlZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjExNTg5

ODI8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEw

LjExMTEvai4xMzY1LTI3OTYuMjAxMC4wMjMxMi54PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48

bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5TdGVn

bWF5cjwvQXV0aG9yPjxZZWFyPjIwMDM8L1llYXI+PFJlY051bT4zMjY5PC9SZWNOdW0+PHJlY29y

ZD48cmVjLW51bWJlcj4zMjY5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0iYWU1emV3dHYzdnNleGtlOWV3Y3Z0czlrMmZhcngycmF4cjV0IiB0aW1lc3RhbXA9

IjE1NTM4NjkxNjgiPjMyNjk8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PlN0ZWdtYXlyLCBCLjwvYXV0aG9yPjxhdXRob3I+THVuZGJlcmcsIFYuPC9hdXRob3I+PGF1dGhv

cj5Bc3BsdW5kLCBLLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRy

ZXNzPk1lZGljaW5lLCBEZXBhcnRtZW50IG9mIFB1YmxpYyBIZWFsdGggYW5kIENsaW5pY2FsIE1l

ZGljaW5lIFVtZWEgVW5pdmVyc2l0eSBVbWVhLCBTd2VkZW4uIGJpcmdpdHRhLnN0ZWdtYXlyQG1l

ZGljaW5lLnVtdS5zZTwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlRoZSBldmVudHMgcmVn

aXN0cmF0aW9uIGFuZCBzdXJ2ZXkgcHJvY2VkdXJlcyBpbiB0aGUgTm9ydGhlcm4gU3dlZGVuIE1P

TklDQSBQcm9qZWN0PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPlNjYW5kIEogUHVibGljIEhlYWx0

aCBTdXBwbDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxl

PlNjYW5kaW5hdmlhbiBqb3VybmFsIG9mIHB1YmxpYyBoZWFsdGguIFN1cHBsZW1lbnQ8L2Z1bGwt

dGl0bGU+PGFiYnItMT5TY2FuZCBKIFB1YmxpYyBIZWFsdGggU3VwcGw8L2FiYnItMT48L3Blcmlv

ZGljYWw+PHBhZ2VzPjktMTc8L3BhZ2VzPjx2b2x1bWU+NjE8L3ZvbHVtZT48ZWRpdGlvbj4yMDAz

LzEyLzA5PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5DYXJkaW92YXNjdWxhciBEaXNlYXNl

cy8qZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkRhdGEgQ29sbGVjdGlvbjwva2V5d29y

ZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+U3dlZGVuL2VwaWRlbWlvbG9neTwv

a2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDAzPC95ZWFyPjwvZGF0ZXM+PGlzYm4+

MTQwMy00OTU2IChQcmludCkmI3hEOzE0MDMtNDk0OCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lv

bi1udW0+MTQ2NjAyNDI8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0

dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzE0NjYwMjQyPC91cmw+PC9yZWxhdGVk

LXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDgwLzE0MDM0OTUwMzEw

MDAxNDQxPC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3Rl

Pn==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Fcmlrc3NvbjwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+

PFJlY051bT4xNjU8L1JlY051bT48RGlzcGxheVRleHQ+KDEsIDIpPC9EaXNwbGF5VGV4dD48cmVj

b3JkPjxyZWMtbnVtYmVyPjE2NTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF

TiIgZGItaWQ9ImFlNXpld3R2M3ZzZXhrZTlld2N2dHM5azJmYXJ4MnJheHI1dCIgdGltZXN0YW1w

PSIxMzE3MTYxMzg3Ij4xNjU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PkVyaWtzc29uLCBNLjwvYXV0aG9yPjxhdXRob3I+SG9sbWdyZW4sIEwuPC9hdXRob3I+PGF1dGhv

cj5KYW5sZXJ0LCBVLjwvYXV0aG9yPjxhdXRob3I+SmFuc3NvbiwgSi4gSC48L2F1dGhvcj48YXV0

aG9yPkx1bmRibGFkLCBELjwvYXV0aG9yPjxhdXRob3I+U3RlZ21heXIsIEIuPC9hdXRob3I+PGF1

dGhvcj5Tb2RlcmJlcmcsIFMuPC9hdXRob3I+PGF1dGhvcj5FbGlhc3NvbiwgTS48L2F1dGhvcj48

L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFB1Ymxp

YyBIZWFsdGggYW5kIENsaW5pY2FsIE1lZGljaW5lLCBVbWVhIFVuaXZlcnNpdHksIFVtZWEsIFN3

ZWRlbi4gbWFyaWUuZXJpa3Nzb25AbWVkaWNpbi51bXUuc2U8L2F1dGgtYWRkcmVzcz48dGl0bGVz

Pjx0aXRsZT5MYXJnZSBpbXByb3ZlbWVudHMgaW4gbWFqb3IgY2FyZGlvdmFzY3VsYXIgcmlzayBm

YWN0b3JzIGluIHRoZSBwb3B1bGF0aW9uIG9mIG5vcnRoZXJuIFN3ZWRlbjogdGhlIE1PTklDQSBz

dHVkeSAxOTg2LTIwMDk8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SiBJbnRlcm4gTWVkPC9zZWNv

bmRhcnktdGl0bGU+PGFsdC10aXRsZT5KIEludGVybiBNZWQ8L2FsdC10aXRsZT48L3RpdGxlcz48

cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIEludGVybiBNZWQ8L2Z1bGwtdGl0bGU+PGFiYnItMT5K

b3VybmFsIG9mIGludGVybmFsIG1lZGljaW5lPC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVy

aW9kaWNhbD48ZnVsbC10aXRsZT5KIEludGVybiBNZWQ8L2Z1bGwtdGl0bGU+PGFiYnItMT5Kb3Vy

bmFsIG9mIGludGVybmFsIG1lZGljaW5lPC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+

MjE5LTMxPC9wYWdlcz48dm9sdW1lPjI2OTwvdm9sdW1lPjxudW1iZXI+MjwvbnVtYmVyPjxlZGl0

aW9uPjIwMTAvMTIvMTc8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3Jk

PjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+QW50aWNob2xlc3RlcmVtaWMgQWdlbnRz

L3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5CbG9vZCBQcmVzc3VyZS9waHlzaW9s

b2d5PC9rZXl3b3JkPjxrZXl3b3JkPkJvZHkgTWFzcyBJbmRleDwva2V5d29yZD48a2V5d29yZD5D

YXJkaW92YXNjdWxhciBEaXNlYXNlcy8qZXBpZGVtaW9sb2d5LypldGlvbG9neS9waHlzaW9wYXRo

b2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+Q2hvbGVzdGVyb2wvYmxvb2Q8L2tleXdvcmQ+PGtleXdv

cmQ+RGlhYmV0ZXMgTWVsbGl0dXMvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkVkdWNh

dGlvbmFsIFN0YXR1czwva2V5d29yZD48a2V5d29yZD5FcGlkZW1pb2xvZ2ljIE1ldGhvZHM8L2tl

eXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48

a2V5d29yZD5IeXBlcnRlbnNpb24vY29tcGxpY2F0aW9ucy9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+

PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5

d29yZD5PYmVzaXR5L2NvbXBsaWNhdGlvbnMvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3Jk

PlNtb2tpbmcvYWR2ZXJzZSBlZmZlY3RzL2VwaWRlbWlvbG9neS90cmVuZHM8L2tleXdvcmQ+PGtl

eXdvcmQ+U3dlZGVuL2VwaWRlbWlvbG9neTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVh

cj4yMDExPC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+RmViPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0

ZXM+PGlzYm4+MTM2NS0yNzk2IChFbGVjdHJvbmljKSYjeEQ7MDk1NC02ODIwIChMaW5raW5nKTwv

aXNibj48YWNjZXNzaW9uLW51bT4yMTE1ODk4MjwvYWNjZXNzaW9uLW51bT48d29yay10eXBlPlJl

c2VhcmNoIFN1cHBvcnQsIE5vbi1VLlMuIEdvdiZhcG9zO3Q8L3dvcmstdHlwZT48dXJscz48cmVs

YXRlZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjExNTg5

ODI8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEw

LjExMTEvai4xMzY1LTI3OTYuMjAxMC4wMjMxMi54PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48

bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5TdGVn

bWF5cjwvQXV0aG9yPjxZZWFyPjIwMDM8L1llYXI+PFJlY051bT4zMjY5PC9SZWNOdW0+PHJlY29y

ZD48cmVjLW51bWJlcj4zMjY5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0iYWU1emV3dHYzdnNleGtlOWV3Y3Z0czlrMmZhcngycmF4cjV0IiB0aW1lc3RhbXA9

IjE1NTM4NjkxNjgiPjMyNjk8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PlN0ZWdtYXlyLCBCLjwvYXV0aG9yPjxhdXRob3I+THVuZGJlcmcsIFYuPC9hdXRob3I+PGF1dGhv

cj5Bc3BsdW5kLCBLLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRy

ZXNzPk1lZGljaW5lLCBEZXBhcnRtZW50IG9mIFB1YmxpYyBIZWFsdGggYW5kIENsaW5pY2FsIE1l

ZGljaW5lIFVtZWEgVW5pdmVyc2l0eSBVbWVhLCBTd2VkZW4uIGJpcmdpdHRhLnN0ZWdtYXlyQG1l

ZGljaW5lLnVtdS5zZTwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlRoZSBldmVudHMgcmVn

aXN0cmF0aW9uIGFuZCBzdXJ2ZXkgcHJvY2VkdXJlcyBpbiB0aGUgTm9ydGhlcm4gU3dlZGVuIE1P

TklDQSBQcm9qZWN0PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPlNjYW5kIEogUHVibGljIEhlYWx0

aCBTdXBwbDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxl

PlNjYW5kaW5hdmlhbiBqb3VybmFsIG9mIHB1YmxpYyBoZWFsdGguIFN1cHBsZW1lbnQ8L2Z1bGwt

dGl0bGU+PGFiYnItMT5TY2FuZCBKIFB1YmxpYyBIZWFsdGggU3VwcGw8L2FiYnItMT48L3Blcmlv

ZGljYWw+PHBhZ2VzPjktMTc8L3BhZ2VzPjx2b2x1bWU+NjE8L3ZvbHVtZT48ZWRpdGlvbj4yMDAz

LzEyLzA5PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5DYXJkaW92YXNjdWxhciBEaXNlYXNl

cy8qZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkRhdGEgQ29sbGVjdGlvbjwva2V5d29y

ZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+U3dlZGVuL2VwaWRlbWlvbG9neTwv

a2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDAzPC95ZWFyPjwvZGF0ZXM+PGlzYm4+

MTQwMy00OTU2IChQcmludCkmI3hEOzE0MDMtNDk0OCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lv

bi1udW0+MTQ2NjAyNDI8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0

dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzE0NjYwMjQyPC91cmw+PC9yZWxhdGVk

LXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDgwLzE0MDM0OTUwMzEw

MDAxNDQxPC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3Rl

Pn==

ADDIN EN.CITE.DATA (1, 2)Participants were randomly assigned examination in the morning or after lunch and hence the fasting period was at least 8 hours or at least 4 hours, respectively. In practice, this implies an overnight fast for those examined in the morning (approximately 60% of all participants).Blood pressureIn the surveys 1986 to 2004, blood pressure was measured twice in the sitting position, after a 5-min rest, using the Hawksley random-zero sphygmomanometer, and the mean value was recorded.From 2009 onwards, the Omron M7 monitor was used. Hypertension was defined as mean systolic blood pressure ≥140 mmHg and? or mean diastolic blood pressure ≥90 mmHg, and? or treatment with antihypertensive medication during the 2 weeks before the survey. In 2009, blood pressure was measured with both methods in a subsample ADDIN EN.CITE <EndNote><Cite><Author>Eriksson</Author><Year>2012</Year><RecNum>3273</RecNum><DisplayText>(3)</DisplayText><record><rec-number>3273</rec-number><foreign-keys><key app="EN" db-id="ae5zewtv3vsexke9ewcvts9k2farx2raxr5t" timestamp="1554369247">3273</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Eriksson, M.</author><author>Carlberg, B.</author><author>Jansson, J. H.</author></authors></contributors><auth-address>Department of Statistics, Umea School of Business and Economics Umea University, Umea, Sweden. marie.eriksson@stat.umu.se</auth-address><titles><title>Comparison of blood pressure measurements between an automated oscillometric device and a Hawksley random-zero sphygmomanometer in the northern Sweden MONICA study</title><secondary-title>Blood Press Monit</secondary-title></titles><periodical><full-title>Blood Press Monit</full-title></periodical><pages>164-70</pages><volume>17</volume><number>4</number><edition>2012/07/12</edition><keywords><keyword>Adult</keyword><keyword>Aged</keyword><keyword>*Blood Pressure</keyword><keyword>Blood Pressure Determination/*instrumentation</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Hypertension/diagnosis</keyword><keyword>Linear Models</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Oscillometry/*instrumentation</keyword><keyword>*Sphygmomanometers</keyword><keyword>Sweden</keyword></keywords><dates><year>2012</year><pub-dates><date>Aug</date></pub-dates></dates><isbn>1473-5725 (Electronic)&#xD;1359-5237 (Linking)</isbn><accession-num>22781634</accession-num><urls><related-urls><url>;(3).Blood-glucoseAn Oral Glucose Tolerance Test (OGTT) was performed according to WHO standards in those randomly assigned a morning examination time ADDIN EN.CITE <EndNote><Cite><RecNum>3265</RecNum><DisplayText>(4)</DisplayText><record><rec-number>3265</rec-number><foreign-keys><key app="EN" db-id="ae5zewtv3vsexke9ewcvts9k2farx2raxr5t" timestamp="1553868941">3265</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title>World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva, World Health Org, 1999.</title></titles><dates></dates><urls></urls></record></Cite></EndNote>(4).Venous plasma was used for glucose analysis and, until 1999, the hexokinase method (Boehringer Mannheim Automated analysis for BM/Hitachi system 717) was used in a single laboratory. Since 2004, a Hemocue benchtop analyser (Quest Diagnostics, Madison,NJ, USA) was used. In 2004, a parallel analysis was undertaken in 195 oral glucose tolerance test samples using both the old Boehringer and the new Hemocue methods. The Pearson correlation coefficients for fasting plasma glucose and 2-h post-load plasma glucose for the two methods were 0.84 and 0.98, respectively (all P < 0.0005). Linear regression-derived equations using glucose concentrations with the old method and the new method have been constructed PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MaWxqYTwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+PFJl

Y051bT45MTk8L1JlY051bT48RGlzcGxheVRleHQ+KDUpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxy

ZWMtbnVtYmVyPjkxOTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGIt

aWQ9ImFlNXpld3R2M3ZzZXhrZTlld2N2dHM5azJmYXJ4MnJheHI1dCIgdGltZXN0YW1wPSIxMzg1

OTg3NDcxIj45MTk8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkxpbGph

LCBNLjwvYXV0aG9yPjxhdXRob3I+RWxpYXNzb24sIE0uPC9hdXRob3I+PGF1dGhvcj5Fcmlrc3Nv

biwgTS48L2F1dGhvcj48YXV0aG9yPlNvZGVyYmVyZywgUy48L2F1dGhvcj48L2F1dGhvcnM+PC9j

b250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFB1YmxpYyBIZWFsdGggYW5k

IENsaW5pY2FsIE1lZGljaW5lLCBGYW1pbHkgTWVkaWNpbmUsIFVtZWEgVW5pdmVyc2l0eSwgVW1l

YSwgU3dlZGVuLiBtaWthZWwubGlsamFAamxsLnNlPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0

bGU+QSByaWdodHdhcmQgc2hpZnQgb2YgdGhlIGRpc3RyaWJ1dGlvbiBvZiBmYXN0aW5nIGFuZCBw

b3N0LWxvYWQgZ2x1Y29zZSBpbiBub3J0aGVybiBTd2VkZW4gYmV0d2VlbiAxOTkwIGFuZCAyMDA5

IGFuZCBpdHMgcHJlZGljdG9ycy4gRGF0YSBmcm9tIHRoZSBOb3J0aGVybiBTd2VkZW4gTU9OSUNB

IHN0dWR5PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkRpYWJldCBNZWQ8L3NlY29uZGFyeS10aXRs

ZT48YWx0LXRpdGxlPkRpYWJldGljIG1lZGljaW5lIDogYSBqb3VybmFsIG9mIHRoZSBCcml0aXNo

IERpYWJldGljIEFzc29jaWF0aW9uPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1

bGwtdGl0bGU+RGlhYmV0IE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjEwNTQt

NjI8L3BhZ2VzPjx2b2x1bWU+MzA8L3ZvbHVtZT48bnVtYmVyPjk8L251bWJlcj48ZWRpdGlvbj4y

MDEzLzA0LzE3PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5

d29yZD5CaW9tYXJrZXJzL2Jsb29kPC9rZXl3b3JkPjxrZXl3b3JkPkJsb29kIEdsdWNvc2UvKmFu

YWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPkNvaG9ydCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3Jk

PkNyb3NzLVNlY3Rpb25hbCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPkRpYWJldGVzIE1lbGxp

dHVzLCBUeXBlIDIvYmxvb2QvKmVwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5GYXN0aW5n

PC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5HbHVjb3NlIEludG9s

ZXJhbmNlL2Jsb29kLyplcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+R2x1Y29zZSBUb2xl

cmFuY2UgVGVzdDwva2V5d29yZD48a2V5d29yZD5IZWFsdGggU3VydmV5czwva2V5d29yZD48a2V5

d29yZD4qSGVhbHRoIFRyYW5zaXRpb248L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3Jk

PjxrZXl3b3JkPkxlcHRpbi8qYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48

a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5d29yZD4qTW9kZWxzLCBCaW9sb2dpY2Fs

PC9rZXl3b3JkPjxrZXl3b3JkPlByZWRpYWJldGljIFN0YXRlL2Jsb29kLyplcGlkZW1pb2xvZ3k8

L2tleXdvcmQ+PGtleXdvcmQ+UHJldmFsZW5jZTwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3Rv

cnM8L2tleXdvcmQ+PGtleXdvcmQ+U2V4IEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+U3dlZGVu

L2VwaWRlbWlvbG9neTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEzPC95ZWFy

PjxwdWItZGF0ZXM+PGRhdGU+U2VwPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTQ2

NC01NDkxIChFbGVjdHJvbmljKSYjeEQ7MDc0Mi0zMDcxIChMaW5raW5nKTwvaXNibj48YWNjZXNz

aW9uLW51bT4yMzU4Njg1NDwvYWNjZXNzaW9uLW51bT48d29yay10eXBlPlJlc2VhcmNoIFN1cHBv

cnQsIE5vbi1VLlMuIEdvdiZhcG9zO3Q8L3dvcmstdHlwZT48dXJscz48cmVsYXRlZC11cmxzPjx1

cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjM1ODY4NTQ8L3VybD48L3Jl

bGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjExMTEvZG1lLjEy

MjA4PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MaWxqYTwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+PFJl

Y051bT45MTk8L1JlY051bT48RGlzcGxheVRleHQ+KDUpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxy

ZWMtbnVtYmVyPjkxOTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGIt

aWQ9ImFlNXpld3R2M3ZzZXhrZTlld2N2dHM5azJmYXJ4MnJheHI1dCIgdGltZXN0YW1wPSIxMzg1

OTg3NDcxIj45MTk8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkxpbGph

LCBNLjwvYXV0aG9yPjxhdXRob3I+RWxpYXNzb24sIE0uPC9hdXRob3I+PGF1dGhvcj5Fcmlrc3Nv

biwgTS48L2F1dGhvcj48YXV0aG9yPlNvZGVyYmVyZywgUy48L2F1dGhvcj48L2F1dGhvcnM+PC9j

b250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFB1YmxpYyBIZWFsdGggYW5k

IENsaW5pY2FsIE1lZGljaW5lLCBGYW1pbHkgTWVkaWNpbmUsIFVtZWEgVW5pdmVyc2l0eSwgVW1l

YSwgU3dlZGVuLiBtaWthZWwubGlsamFAamxsLnNlPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0

bGU+QSByaWdodHdhcmQgc2hpZnQgb2YgdGhlIGRpc3RyaWJ1dGlvbiBvZiBmYXN0aW5nIGFuZCBw

b3N0LWxvYWQgZ2x1Y29zZSBpbiBub3J0aGVybiBTd2VkZW4gYmV0d2VlbiAxOTkwIGFuZCAyMDA5

IGFuZCBpdHMgcHJlZGljdG9ycy4gRGF0YSBmcm9tIHRoZSBOb3J0aGVybiBTd2VkZW4gTU9OSUNB

IHN0dWR5PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkRpYWJldCBNZWQ8L3NlY29uZGFyeS10aXRs

ZT48YWx0LXRpdGxlPkRpYWJldGljIG1lZGljaW5lIDogYSBqb3VybmFsIG9mIHRoZSBCcml0aXNo

IERpYWJldGljIEFzc29jaWF0aW9uPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1

bGwtdGl0bGU+RGlhYmV0IE1lZDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjEwNTQt

NjI8L3BhZ2VzPjx2b2x1bWU+MzA8L3ZvbHVtZT48bnVtYmVyPjk8L251bWJlcj48ZWRpdGlvbj4y

MDEzLzA0LzE3PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5

d29yZD5CaW9tYXJrZXJzL2Jsb29kPC9rZXl3b3JkPjxrZXl3b3JkPkJsb29kIEdsdWNvc2UvKmFu

YWx5c2lzPC9rZXl3b3JkPjxrZXl3b3JkPkNvaG9ydCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3Jk

PkNyb3NzLVNlY3Rpb25hbCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPkRpYWJldGVzIE1lbGxp

dHVzLCBUeXBlIDIvYmxvb2QvKmVwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5GYXN0aW5n

PC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5HbHVjb3NlIEludG9s

ZXJhbmNlL2Jsb29kLyplcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+R2x1Y29zZSBUb2xl

cmFuY2UgVGVzdDwva2V5d29yZD48a2V5d29yZD5IZWFsdGggU3VydmV5czwva2V5d29yZD48a2V5

d29yZD4qSGVhbHRoIFRyYW5zaXRpb248L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3Jk

PjxrZXl3b3JkPkxlcHRpbi8qYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48

a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5d29yZD4qTW9kZWxzLCBCaW9sb2dpY2Fs

PC9rZXl3b3JkPjxrZXl3b3JkPlByZWRpYWJldGljIFN0YXRlL2Jsb29kLyplcGlkZW1pb2xvZ3k8

L2tleXdvcmQ+PGtleXdvcmQ+UHJldmFsZW5jZTwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3Rv

cnM8L2tleXdvcmQ+PGtleXdvcmQ+U2V4IEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+U3dlZGVu

L2VwaWRlbWlvbG9neTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEzPC95ZWFy

PjxwdWItZGF0ZXM+PGRhdGU+U2VwPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTQ2

NC01NDkxIChFbGVjdHJvbmljKSYjeEQ7MDc0Mi0zMDcxIChMaW5raW5nKTwvaXNibj48YWNjZXNz

aW9uLW51bT4yMzU4Njg1NDwvYWNjZXNzaW9uLW51bT48d29yay10eXBlPlJlc2VhcmNoIFN1cHBv

cnQsIE5vbi1VLlMuIEdvdiZhcG9zO3Q8L3dvcmstdHlwZT48dXJscz48cmVsYXRlZC11cmxzPjx1

cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjM1ODY4NTQ8L3VybD48L3Jl

bGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjExMTEvZG1lLjEy

MjA4PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA (5). Plasma lipidsAll measurements of total cholesterol have been done at a central laboratory. Between 1986 and 1994, total cholesterol was determined by an enzymatic method (BM Monotest Cholesterol CHOD-PAP, Boehringer Mannheim, GmbH, Germany), and since 1999 a dry chemistry method was used (Vitros 950, Kodak Echtachem, USA). The measurement of total cholesterol is accredited by the national accreditation body, with a CV of 3.6% at 3.9 mmol/L and 3.1% at 6.7 mmol/L (7-8). HDL was measured 1986, 1990, and 1994, and TG was measured 1986, 1990, 1994, 1999 and 2004. See page 9–11, cholesterol results from the 1986, 1990 and 1994 surveys have been converted to the new method used from 1999 (1.4% adjustment). HeightHeight was measured without shoes to the nearest cm using a calibrated wall mounted height rod or height rod that is mount onto the scale.WeightThe subjects wore light clothes and no shoes, and weight was measured to the nearest 0.1 kg on a balance scale (calibrated daily) from 1986 to 1994, and on an electronic scale from 1999 onwards.WaistThe waist and hip circumferences were measured in standing position with the feet fairly close together (12?15 cm apart). Tight undergarments were released or taken off before measuring the waist circumference, which was measured midway between the lower rib margin and the iliac crest. At the time of measuring, the subject was asked to exhale gently. The hip circumference was measured at the maximum circumference over the buttocks to the nearest 0.5 cm.References, MONICA ADDIN EN.REFLIST 1.Eriksson M, Holmgren L, Janlert U, Jansson JH, Lundblad D, Stegmayr B, et al. Large improvements in major cardiovascular risk factors in the population of northern Sweden: the MONICA study 1986-2009. Journal of internal medicine. 2011;269(2):219-31.2.Stegmayr B, Lundberg V, Asplund K. The events registration and survey procedures in the Northern Sweden MONICA Project. Scand J Public Health Suppl. 2003;61:9-17.3.Eriksson M, Carlberg B, Jansson JH. Comparison of blood pressure measurements between an automated oscillometric device and a Hawksley random-zero sphygmomanometer in the northern Sweden MONICA study. Blood Press Monit. 2012;17(4):164-70.4.World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva, World Health Org, 1999.5.Lilja M, Eliasson M, Eriksson M, Soderberg S. A rightward shift of the distribution of fasting and post-load glucose in northern Sweden between 1990 and 2009 and its predictors. Data from the Northern Sweden MONICA study. Diabet Med. 2013;30(9):1054-62.Mammographic Screening ProjectCohortSamples (mostly nonfasting) and data are collected in connection with mammography screenings 1995-2006HeightAll years self- reportedWeightAll years self- reportedRecommendations for interpretation of outlier valuesValues within the indicated levels below are suggested to be handled as missing values. All outliers have been checked for possible mistake in the data handling.ParameterValueHeight <130 cm or >210 cmWeight <35 KgBody Mass Index >70S-Cholesterol <2.0 mmol/LHDL >7 mmol/LS-Triglycerides <0.15 mmol/L or >20 mmol/LConversion of sitting to recumbent blood pressure values and vice versa (VIP) In the VIP-cohort, blood pressure was measured with subjects in recumbent (supine) position until September 1st 2009 and from that date with subjects in sitting position.The differences in blood pressure values between measurements in the two various positions, recumbent or sitting, are negligible in a clinical point of view. However, in a dataset from the VIP-cohort where blood pressure was measured on the same individuals in the two different positions, a significant difference for both the systolic and diastolic values was found. Based on this calculation the diastolic value was in average 2.5 mm higher measured at sitting position and the systolic value 0.8 mm higher in this position. This is in line with previous findings on different populations (1, 2). In these studies, the diastolic values were higher when measured in sitting position, while the effect on the systolic blood pressure showed a slight decreased. We therefore recommend an addition with 2.5 mm for conversion of the diastolic blood pressure from recumbent to sitting position, and no need for conversion for the systolic measurements.A data set with blood pressure values from 653 VIP-participants at age 40, 50 or 60 years and measured in both positions is available after contacting EBF.The figures show correlation between the blood pressure values measured in two various position, recumbent or sitting. The illustrations are based on a data set with 653 VIP-participants at age 40, 50 or 60 years, measured at both positions.References VIP:Kahan T. R?tt m?tt blodtryck tack! L?kartidningen 2009; 106: 1349-1350.Kuwabaraa,M, Haradab K, Hishikib Y, Karioa K. Validation of an automatic device for the self-measurement of blood pressure in sitting and supine positions according to the ANSI/AAMI/ISO81060-2:2013 guidelines: the Omron HEM-9700T. Blood Pressure Monitoring 2019; 24: 146–150.Cholesterol and triglycerides in the VIP-cohort, correlation between two different methods for measurement Various methods have been used to calculate cholesterol and triglyceride values before and after 2009-09-01. We have previously recommended a certain algorithm to be able to compare older data with newer ones, where different methods have been used.The algorithm has been calculated by linear regression but since there are random errors in both parameters, this method is not always optimal.We have examined the material where there are measurement values from both methods and the difference in mean and median values is only 2-3%. The previous recommendation introduced a larger error, 7-10%, than the real difference.Therefore, we recommend not to use any algorithm for VIP data. The methods are comparable. However, it should be kept in mind that for triglycerides, the min value with the old method is = 0.8.Blood lipids were measured by two methods; 1985 – 2009-08-31 on a reflotron at local health centers. Samples with high cholesterol (>6.5 mmol/l) and/or triglycerides values were re-analyzed at Clinical Chemistry Laboratory for cholesterol, triglycerides and HDL. Reference value for high cholesterol in individuals with known cardiovascular disease was set at >5.2 mmol/l. From 2009-09-01 blood lipids were analyzed by an enzymatic method at Clinical Chemistry Laboratory. A dataset with samples that are analyzed with both methods is available. Regarding triglycerides there are data from 838 VIP-participants and regarding cholesterol from 1197 VIP-participants. This dataset is stored at EBF and available after contacting the unit.The figures show correlation between the two methods used for blood lipid analyses. The illustrations are based on a data set with 1197 VIP-participants for cholesterol and 837 VIP-participants for triglycerides (old method = reflotron, new method = enzymatic method).Transformation of cholesterol levels between old and new (1999) analysis method in the MONICA surveyIntroductionThe analysis method to determine the total cholesterol levels in blood/plasma has changed between two screenings in the MONICA project. Hence the cholesterol levels obtained at the screening 1999 need to be transformed in order to compare them with previous screenings. For this purpose, 159 of the samples obtained in 1994 were reanalysed using the new analysis method.Statistical methodsA linear regression model yi=+xi+ij, where yi is the cholesterol level with the 1994 (old) method and xi is the level with the 1999 (new) method, was applied. The random error term, ij, is assumed to be independent normally distributed. Furthermore, since there were indications and is reason to believe that the variance increases with higher cholesterol values, the parameters were estimated with weighted least squares, with weight 1/x. ResultsThere was one very extreme value. Hence, the analysis was carried out both with that observation included as well as excluded.Figure SEQ Figure \* ARABIC 1. Scatterplot of old vs. new analysis method, the line represent equality.Figure SEQ Figure \* ARABIC 2. The cholesterol values vs. the rank (ordered number) of cholesterol for the old analysis method.All observationsThe regression line was estimated to:cholesterol (old) = 0.051 + 1.004*cholesterol (new)One outlier removedThe fitted model was:cholesterol (old) = 0.010 + 1.014*cholesterol (new)..Figure SEQ Figure \* ARABIC 3. Scatterplot of old vs. new analysis method with fitted regression line (outlier excluded).Figure SEQ Figure \* ARABIC 4. Residual plot: residuals vs. predicted values.Conclusions/recommendationsWhen comparing cholesterol levels from the two different analysis methods the transformation obtained by excluding one outlier is recommended i.e. cholesterol (old) = 0.010 + 1.014*cholesterol (new). The 1.4% adjustment fits well with the difference between the new and old method observed in Figure 1. Therefore the 1.4% transformation based on linear regression can be justified and this conversion has been done for these subjects. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download